Breaking News, Collaborations & Alliances

PharmAbcine Enters Partnership with Thermo Fisher

Will develop and manufacture Thermo Fisher’s immune checkpoint blockade, PMC-309 for Phase I

By: Contract Pharma

Contract Pharma Staff

PharmAbcine Inc. has entered into a strategic partnership with Thermo Fisher Scientific for the development and manufacturing of PMC-309, a next-generation immune checkpoint blockade to treat cancer.   Under this agreement, PharmAbcine will take advantage of Thermo Fisher’s Quick to Clinic integrated service offering, a program that accelerates drug development for IND submission for Phase I.   PMC-309 is a novel fully human monoclonal IgG targeting unique epitope of human VISTA (V-domain ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters